Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design.
One of the main challenges of developing an HIV-1 vaccine lies in eliciting immune responses that can overcome the antigenic variability exhibited by HIV. Most HIV-1 vaccine development has focused on inducing immunity to conserved regions of the HIV-1 envelope. However, new studies of the sequence-variable regions of the HIV-1 gp120 envelope glycoprotein have shown that there are conserved immunological and structural features in these regions. Recombinant immunogens that include these features may provide the means to address the antigenic diversity of HIV-1 and induce protective antibodies that can prevent infection with HIV-1.
Zolla-Pazner
Susan
S
Veterans Affairs New York Harbor Healthcare System, Manhattan Campus, New York 10010, USA. Susan.Zolla-Pazner@nyumc.org
Cardozo
Timothy
T
D016915:AIDS Vaccines / Q000737:chemistry / Q000235:genetics* / Q000276:immunology*; D000595:Amino Acid Sequence; D000911:Antibodies, Monoclonal / Q000096:biosynthesis; D057134:Antibodies, Neutralizing / Q000096:biosynthesis; D000940:Antigenic Variation; D017124:Conserved Sequence; D018360:Crystallography, X-Ray; D000939:Epitopes / Q000737:chemistry; D015483:HIV Antibodies / Q000096:biosynthesis; D015699:HIV Envelope Protein gp120 / Q000737:chemistry / Q000235:genetics* / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control*; D015497:HIV-1 / Q000737:chemistry / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D008958:Models, Molecular; D008969:Molecular Sequence Data; D013329:Structure-Activity Relationship
D016915:AIDS Vaccines; D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D000939:Epitopes; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; C514793:gp120 protein, Human immunodeficiency virus 1